Release of a mitogenic factor by splenic Lyt 1+ T-cells from mice treated with SSM, an immunomodulator extracted from human type tubercle bacilli

Richard B Pollard, D. A. Schmitt, H. Sasaki, Y. Hayashi, F. Suzuki

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

A production of the soluble factor activity in culture fluids of murine splenic mononuclear cells (SMNC) treated with SSM, an immunopotentiator extracted from Mycobacterium tuberculosis strain Aoyama B, was investigated. The soluble factor activity was determined as a mitogenic activity released from SMNC of mice previously treated with a 500 μg/kg dose of SSM (primed SMNC). The mitogenic activity was produced when primed SMNC were challenged in vitro with SSM at a concentration of 5 μg/ml. The activity was not produced in culture fluids of primed SMNC treated with anti-Thy 1.2 or anti-Lyt 1.2 monoclonal antibody plus complement followed by a challenge with SSM. However, the production of the activity was not affected by pretreatment of primed SMNC with anti-Lyt 2.2 monoclonal antibody plus complement. Since the non-specific resistance to tumors of mice stimulated with SSM was not demonstrated in mice depleted of Thy 1+ and Lyt 1+ T-cells, and Lyt 1+ T-cells from SSM-treated mice did not show any direct cytotoxic activities against tumor cells in vitro, the soluble factor released from Lyt 1+ T-cells by SSM stimulation may play an important role in developing the non-specific resistance of mice treated with SSM.

Original languageEnglish (US)
Pages (from-to)285-290
Number of pages6
JournalAnticancer Research
Volume10
Issue number2 A
StatePublished - 1990
Externally publishedYes

Fingerprint

Immunologic Factors
Bacillus
T-Lymphocytes
Monoclonal Antibodies
Immunologic Adjuvants
Mycobacterium tuberculosis
Neoplasms

Keywords

  • human type Tubercle bacilli
  • immunomodulator
  • mitogenic factor
  • splenic Lyt 1 T-cells
  • SSM

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Release of a mitogenic factor by splenic Lyt 1+ T-cells from mice treated with SSM, an immunomodulator extracted from human type tubercle bacilli. / Pollard, Richard B; Schmitt, D. A.; Sasaki, H.; Hayashi, Y.; Suzuki, F.

In: Anticancer Research, Vol. 10, No. 2 A, 1990, p. 285-290.

Research output: Contribution to journalArticle

@article{d657a65e2e854ba8ab1620ee8822f3cc,
title = "Release of a mitogenic factor by splenic Lyt 1+ T-cells from mice treated with SSM, an immunomodulator extracted from human type tubercle bacilli",
abstract = "A production of the soluble factor activity in culture fluids of murine splenic mononuclear cells (SMNC) treated with SSM, an immunopotentiator extracted from Mycobacterium tuberculosis strain Aoyama B, was investigated. The soluble factor activity was determined as a mitogenic activity released from SMNC of mice previously treated with a 500 μg/kg dose of SSM (primed SMNC). The mitogenic activity was produced when primed SMNC were challenged in vitro with SSM at a concentration of 5 μg/ml. The activity was not produced in culture fluids of primed SMNC treated with anti-Thy 1.2 or anti-Lyt 1.2 monoclonal antibody plus complement followed by a challenge with SSM. However, the production of the activity was not affected by pretreatment of primed SMNC with anti-Lyt 2.2 monoclonal antibody plus complement. Since the non-specific resistance to tumors of mice stimulated with SSM was not demonstrated in mice depleted of Thy 1+ and Lyt 1+ T-cells, and Lyt 1+ T-cells from SSM-treated mice did not show any direct cytotoxic activities against tumor cells in vitro, the soluble factor released from Lyt 1+ T-cells by SSM stimulation may play an important role in developing the non-specific resistance of mice treated with SSM.",
keywords = "human type Tubercle bacilli, immunomodulator, mitogenic factor, splenic Lyt 1 T-cells, SSM",
author = "Pollard, {Richard B} and Schmitt, {D. A.} and H. Sasaki and Y. Hayashi and F. Suzuki",
year = "1990",
language = "English (US)",
volume = "10",
pages = "285--290",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "2 A",

}

TY - JOUR

T1 - Release of a mitogenic factor by splenic Lyt 1+ T-cells from mice treated with SSM, an immunomodulator extracted from human type tubercle bacilli

AU - Pollard, Richard B

AU - Schmitt, D. A.

AU - Sasaki, H.

AU - Hayashi, Y.

AU - Suzuki, F.

PY - 1990

Y1 - 1990

N2 - A production of the soluble factor activity in culture fluids of murine splenic mononuclear cells (SMNC) treated with SSM, an immunopotentiator extracted from Mycobacterium tuberculosis strain Aoyama B, was investigated. The soluble factor activity was determined as a mitogenic activity released from SMNC of mice previously treated with a 500 μg/kg dose of SSM (primed SMNC). The mitogenic activity was produced when primed SMNC were challenged in vitro with SSM at a concentration of 5 μg/ml. The activity was not produced in culture fluids of primed SMNC treated with anti-Thy 1.2 or anti-Lyt 1.2 monoclonal antibody plus complement followed by a challenge with SSM. However, the production of the activity was not affected by pretreatment of primed SMNC with anti-Lyt 2.2 monoclonal antibody plus complement. Since the non-specific resistance to tumors of mice stimulated with SSM was not demonstrated in mice depleted of Thy 1+ and Lyt 1+ T-cells, and Lyt 1+ T-cells from SSM-treated mice did not show any direct cytotoxic activities against tumor cells in vitro, the soluble factor released from Lyt 1+ T-cells by SSM stimulation may play an important role in developing the non-specific resistance of mice treated with SSM.

AB - A production of the soluble factor activity in culture fluids of murine splenic mononuclear cells (SMNC) treated with SSM, an immunopotentiator extracted from Mycobacterium tuberculosis strain Aoyama B, was investigated. The soluble factor activity was determined as a mitogenic activity released from SMNC of mice previously treated with a 500 μg/kg dose of SSM (primed SMNC). The mitogenic activity was produced when primed SMNC were challenged in vitro with SSM at a concentration of 5 μg/ml. The activity was not produced in culture fluids of primed SMNC treated with anti-Thy 1.2 or anti-Lyt 1.2 monoclonal antibody plus complement followed by a challenge with SSM. However, the production of the activity was not affected by pretreatment of primed SMNC with anti-Lyt 2.2 monoclonal antibody plus complement. Since the non-specific resistance to tumors of mice stimulated with SSM was not demonstrated in mice depleted of Thy 1+ and Lyt 1+ T-cells, and Lyt 1+ T-cells from SSM-treated mice did not show any direct cytotoxic activities against tumor cells in vitro, the soluble factor released from Lyt 1+ T-cells by SSM stimulation may play an important role in developing the non-specific resistance of mice treated with SSM.

KW - human type Tubercle bacilli

KW - immunomodulator

KW - mitogenic factor

KW - splenic Lyt 1 T-cells

KW - SSM

UR - http://www.scopus.com/inward/record.url?scp=0025351170&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025351170&partnerID=8YFLogxK

M3 - Article

C2 - 2346302

AN - SCOPUS:0025351170

VL - 10

SP - 285

EP - 290

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 2 A

ER -